FDA Approves Briumvi to Treat Relapsing Multiple Sclerosis
On December 28, 2022, the U.S. Food items and Drug Administration (Fda) permitted Briumvi (ublituximab), a illness-modifying therapy (DMT) to handle relapsing types of numerous sclerosis (RMS) in older people,…